Risk Stratification in ccRCC: The Impact in Patient Populations

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

EP: 11.Top-Line Results of the Phase 3 ZIRCON Study

Now Viewing

EP: 12.Risk Stratification in ccRCC: The Impact in Patient Populations

EP: 13.Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

EP: 14.Overcoming Challenges for Wider Adoption of TLX250

Molecular Imaging in Risk Stratification and Adjuvant Therapy

Main Discussion Topics:

• Potential role in identifying patients appropriate for adjuvant pembrolizumab after nephrectomy
• Possible utility for improving detection of occult metastatic disease
• Could help identify patients needing more intensive therapy beyond single-agent approaches
• May also identify patients who could be spared morbidity of unnecessary treatment

Key Points for Physicians:

• Molecular imaging could identify occult metastatic disease missed by conventional imaging.
• Patients with positive findings outside the primary tumor may benefit from combination therapy rather than single-agent therapy.
• Patients with negative scans might be candidates for de-escalation of therapy.
• Represents a significant opportunity for clinical trials and personalized approaches.

Notable Insights:

Similar to the evolution in prostate cancer management, molecular imaging in RCC may fundamentally change staging and treatment intensity decisions.

Clinical Significance:

This technology could help tailor treatment intensity, potentially intensifying therapy for those with occult metastatic disease while sparing others from unnecessary treatment.